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Abstract
Background. To review published studies on the cost-
effectiveness of the use of irbesartan for treatment
of advance overt nephropathy in patients with type 2
diabetes and hypertension.
Methods. Articles were identiﬁed based on a search of
the PubMed databases using the keywords ‘irbesartan’,
‘ESRD’, ‘cost-effectiveness’, ‘nephropathy’ and ‘costs’,
and by personal communication with the authors.
Only studies published in the last 10 years were
included. All costs data from the cost-effectiveness
studies were inﬂated to 2003 Euros using published
governmental conversion tables.
Results. Seven published studies were identiﬁed, span-
ning the following country settings: the US, Belgium
and France, Germany, Hungary, Italy, Spain, and
the UK. In each, the same pharmacoeconomic
model was adapted using country-speciﬁc data to
project and evaluate the clinical and cost outcomes
of the treatment arms of the Irbesartan in Diabetic
Nephropathy Trial (IDNT) (irbesartan, amlodipine
or standard blood pressure control). Mean time to
onset of ESRD was 8.23 years for irbesartan, 6.82
years for amlodipine and 6.88 years for the control
(values were the same for Belgium, France, Germany,
Hungary, Italy and Spain as transition probabilities
for progression to ESRD were all derived from the
IDNT). Mean cumulative incidence of ESRD was 36%
with irbesartan, 49% with amlodipine and 45% with
control treatment. Treatment with irbesartan was
projected to improve life expectancy compared to
both amlodipine and control in all seven published
studies. Analysis of total lifetime costs showed that
irbesartan treatment was cost saving compared to the
other two treatment regimens, due to the associated
reduction in ESRD cases. Cost savings with irbesartan
became evident very early; after 2–3 years of treatment
in most settings.
Conclusions. Modelling studies based on the IDNT
published to date suggest that irbesartan treatment
in patients with type 2 diabetes, hypertension and
advanced nephropathy is both life- and cost-saving
compared to amlodipine or control.
Keywords: costs; cost-effectiveness; diabetes; end-stage
renal disease nephropathy; hypertension; irbesartan;
modelling
Introduction
Renal impairment is a serious complication of type 2
diabetes mellitus and becomes life threatening if it
progresses to end-stage renal disease (ESRD). The
huge impact that ESRD has on health and health-
care system budgets is of major concern to healthcare
decision makers. In the Western world, type 2 diabetes
is recognized as the major underlying cause of ESRD
[1], and the incidence of both diabetes and diabetic
renal disease has reached epidemic proportions [2].
ESRD is associated with a substantial clinical and
economic burden that impacts signiﬁcantly on health-
care systems. Throughout the US and Europe the
prevalence of ESRD is increasing. Any measures that
limit its severity and likelihood of leading to death
need to be considered when making decisions on how
best to treat patients with this serious condition. In the
US, more than 300 000 people had ESRD in 1998,
resulting in total medical expenditures of USD 18
billion [3]. The ESRD population increases by6% per
year and for the year 2010 Medicare ESRD expendi-
tures are projected to be USD 28 billion [3]. In the UK,
diabetic nephropathy is the single most common
cause of ESRD with 24% of new ESRD patients
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having diabetes as a co-morbidity [4]. Overall, new
cases of ESRD due to diabetes, renovascular disease
and hypertension almost doubled between 1990
and 1999 [5]. Between 1993 and 1999 there was an
annual increase of 5% in the prevalence of ESRD in
France, where the median survival time of patients
receiving renal replacement therapy is 2.7 years [6–8].
Evidence from Spain supports these ﬁgures, with
recent evidence indicating that type 2 diabetes is
associated with substantial increases in the incidence
of nephropathy and is the major underlying cause of
ESRD, which has a 5-year survival rate of only 54%
[9,10]. By optimally treating patients with type 2
diabetes, renal disease and hypertension it may be
possible to avoid the substantial human and economic
burden of the renal failure associated with patients in
this condition.
Until recently, renoprotection with angiotensin
receptor blockers had not been reported in patients
with type 2 diabetic nephropathy. This changed in
2001 when Lewis et al. [11] published the ﬁndings of
the Irbesartan in Diabetic Nephropathy Trial (IDNT).
The IDNT was a multi-centre, double-blind, placebo-
controlled study in which 1715 hypertensive patients
with type 2 diabetes and advanced overt nephropathy
(protein excretion >900mg per 24 h) were randomized
to treatment with either irbesartan (angiotensin 2
receptor antagonist), amlodipine (a dihydropyridine
calcium channel blocker) or standard blood pressure
control. Patients were tracked for a mean duration
of 2.6 years. To achieve a target blood pressure of
<135/85mmHg throughout the trial, patients in all
three treatment arms received additional standard
antihypertensive medications included in the control
arm if required [diuretics, beta blockers, alpha/beta
blockers, peripheral vasodilators, peripheral adrener-
gic blockers, and central adrenergic blockers, but
excluding angiotensin converting enzyme (ACE) inhi-
bitors, other angiotensin-2-receptor antagonists and
dihydropyridine calcium channel blockers]. The IDNT
showed that treatment with irbesartan in patients
with type 2 diabetes, proteinuria and hypertension
resulted in an 23% reduction in the risk of achiev-
ing the combined primary endpoint of doubling of
serum creatinine (DSC, a strong predictor of progres-
sion to end-stage renal disease), onset of ESRD, or all-
cause mortality, when compared with amlodipine (a
dihydropyridine calcium channel blocker), and a 20%
risk reduction when compared with the control.
The differences between the treatment groups in this
primary endpoint could not be fully explained by
differences in blood pressure control between
therapies, indicating an additional blood pressure-
independent renoprotective effect associated with
irbesartan [11].
The aim of this review is to identify and compare
published studies which projected the cost-effectiveness
and economic impact of irbesartan compared to
amlodipine or control for patients with type 2 diabetes,
overt nephropathy and hypertension derived from the
IDNT.
Literature search and data presentation
Articles for inclusion in this review were identiﬁed
based on a search of the PubMed database using
the keywords ‘irbesartan’, ‘ESRD’, ‘cost-effectiveness’,
‘nephropathy’ and ‘costs’, (singly and in various
combinations) and by personal communication with
the authors of search hits. Only studies published in
the last 10 years were included in the review. Seven
published studies were identiﬁed, spanning the follow-
ing country settings: the US [12], Belgium and France
[13], Germany [14], Hungary [15], Italy [16], Spain [17],
and the UK [18]. In each study a pharmacoeconomic
model was used to project and evaluate the clinical
and cost outcomes of the treatment arms of the IDNT.
The same model was used in all the country settings,
but was adapted to each setting by integrating country-
speciﬁc data. For the purposes of comparison, all costs
data were inﬂated to 2003 Euros using conversion
tables from governmental websites in France (http://
www.insee.fr/en/indicateur/achatfranc.htm), Germany
(http://www.destatis.de/indicators/e/vpi001aj.htm), the
US (http://stats.bls.gov/cpi/) and the UK (http://www.
statistics.gov.uk/pdfdir/cpi1104.pdf ). The latter was
also used to inﬂate costs from Belgium, Hungary and
Spain. To convert UK, US and Hungarian costs to
Euros, the following exchange rates were applied:
E1¼GBP 0.70232; USD 1.30137; HUF 245.660.
Modelling approach
In each of the seven published cost-effectiveness
analyses, a Markov model developed using DATA
Pro decision analysis and simulation software (TreeAge
Software Inc., Williamstown, MA) was used to
simulate the progression of a hypothetical cohort of
patients with type 2 diabetes, advanced overt nephrop-
athy and hypertension to DSC, ESRD and death in
a variety of country settings. Markov models are a
standard method for simulating the course of progres-
sive, long-term diseases, and have been used extensively
in chronic diseases like diabetes [19–21]. The model
used is described in some detail elsewhere [12,13], but a
brief overview has been provided for the purposes of
this review.
The characteristics of the cohort at the start of the
simulation were equivalent to those reported in IDNT
[11]. The model was structured such that patients could
progress through states from advanced overt nephro-
pathy to DSC, ESRD, and death based on treatment-
speciﬁc transition probabilities taken from the IDNT as
previously described by Rodby et al. [12]. The treat-
ment choices simulated in the model were based on
those studied in the IDNT: irbesartan (75–300mg per
day), amlodipine (2.5–10mg per day), or standard
blood pressure control (control arm) to achieve a target
blood pressure of <135/85mmHg. Country-speciﬁc
transition probabilities for the ESRD states (ESRD,
dialysis, transplantation) were utilized in the Belgian,
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French, German, Hungarian, Spanish, UK and US
settings. Mortality rates from the IDNT were assumed
to remain constant for the ﬁrst 10 years of the
simulation in all studies, and then country-speciﬁc
mortality data were used thereafter.
Country-speciﬁc cost inputs were used for drug
treatments (including study drugs and adjuvant
medications as required), renal dialysis and renal
transplantation, and discounting of costs and clinical
beneﬁts was applied according to country-speciﬁc
guidelines. The clinical beneﬁts in the Belgian,
French, and US settings were discounted at a rate
of 3% per annum. In Hungary and Italy an annual
discount rate of 5% was applied. The Spanish study
utilized a discount rate of 6%per annum, and a discount
rate of 1.5% per year was applied to clinical beneﬁts
in the UK setting. Costs in the Belgian, French and
US settings were discounted at a rate of 3% per annum.
In Germany, Hungary and Italy an annual rate of 5%
was applied to costs, and in the Spanish and the UK
settings a rate of 6% was used.
The acquisition costs of medications, management
costs and treatment of ESRD were assumed to remain
constant over the course of each simulation. A third
party payer perspective was taken for all the costs used
in each of the studies reviewed. Since the model was
designed to assess incremental costs only, costs that
were similar between the treatment arms (e.g. visits to
the general practitioner, cardiovascular events, urinary
albumin monitoring and other investigations) were
excluded from the analyses.
Development of ESRD
Data for ESRD projections have been published for
Belgium, France, Germany, Hungary, Italy and Spain,
but not for the UK or the US. Because the transition
probabilities from the states progressing to ESRD were
taken from the IDNT rather than country-speciﬁc data,
the model produced the same projections for all six
countries. Over a 10-year timeframe the mean time to
onset of ESRD was 8.23 years for irbesartan, 6.82 years
for amlodipine and 6.88 years for the control. This
represents differences of 1.41 years between irbesartan
and amlodipine, and 1.35 years between irbesartan and
the control. The mean cumulative incidence of ESRD
over the 10-year timeframe was 36% for irbesartan,
49% for amlodipine and 45% for the control. Since the
UK and the US were simulated using the same model
and transition probabilities, it could be expected that
the results would be the same for these countries
(although these data were not published).
Impact on life expectancy
Life expectancy was improved in the irbesartan group
compared to the amlodipine and control groups in all
the countries reviewed, with the exception of Germany
where values were not reported. In the UK study, life
expectancy projections were reported only in relative
terms, comparing irbesartan to amlodipine and control
(Table 1). In the US study, such projections were only
reported in terms of discounted life years. More life
expectancy data were available, however, for compar-
ison between the studies performed in the other ﬁve
country settings. A consistent pattern was recognizable
in life expectancy projections over a 25-year timeframe
(Table 2). Treatment with irbesartan was projected to
extend life further than that with either amlodipine or
control. This pattern was observed in all seven country
settings with published data (Table 1). Whilst only
discounted life expectancy was reported in the US
study, the values follow the same pattern: the projected
life expectancy was 7.99 years for irbesartan, 7.34 years
for amlodipine and 7.23 years for control.
Table 1 shows the projected improvements in
life expectancy following treatment with irbesartan
compared to both amlodipine and control. Both
undiscounted and discounted life years were recorded
and timeframes of 10 and 25 years were available
Table 1. Summary of projected improvements in life expectancy
Country Lifetime
25-year timeframe 10-year timeframe
Undiscounted LE Discounted LE Undiscounted LE Discounted LE
Irbesartan vs
amlodipine
Irbesartan vs
control
Irbesartan vs
amlodipine
Irbesartan vs
control
Irbesartan vs
amlodipine
Irbesartan vs
control
Irbesartan vs
amlodipine
Irbesartan vs
control
Belgium [13] 0.71 0.91 0.46 0.62 0.13 0.26 0.10 0.22
France [13] 0.69 0.90 0.45 0.61 – – – –
Germany [14] – – – – – – – –
Hungary [15] 0.29 0.63 0.15 0.36 0.07 0.23 0.05 0.16
Italy [16] 0.59 0.84 0.30 0.46 0.15 0.31 0.10 0.22
Spain [17] 0.46 0.75 0.21 0.37 0.1 0.25 0.06 0.17
UK [18] 0.38 0.70 0.31 0.58 0.08 0.23 0.07 0.21
US [12] – – 0.65 0.76 – – 0.19 0.30
LE, life expectancy.
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for comparison (no data were available in the German
setting). In Belgium irbesartan treatment, when com-
pared to amlodipine, was projected to extend life by
0.71 undiscounted life years (0.46 discounted), and by
0.91 undiscounted life years (0.62 discounted) when
compared to control over a 25-year timeframe. A
similar pattern is seen in the other country settings with
the exception of Germany. Undiscounted life expec-
tancy data were not available from the US study, and
no 10-year timeframe data were available for France,
but it has been described as being comparable to that in
the Belgian setting [13].
Summary of costs and cost-effectiveness
A summary of the total mean lifetime costs per patient
are recorded in Table 3 along with the mean costs of
ESRD per patient. A 25-year timeframe was available
for comparison between Belgium, France, Hungary,
Spain and the US. A 10-year timeframe was used in the
German, Italian and UK studies. The total mean
lifetime costs per patient ranged from E41 488; E51 456
in Hungary for irbesartan, amlodipine and the
control, respectively, to E95 198; E122 809 and
E111 886, respectively, in France. These costs in all
eight country settings were less for irbesartan when
compared to amlodipine and the control. ESRD costs
accounted for the majority of total lifetime costs in all
treatment arms (89–99%) where values were reported.
Unfortunately, no data were available regarding the
cost of ESRD in the German and the US setting.
A substantial proportion of the cost savings were
realized in the 10-year, base-case timeframe (Table 4).
Over this period irbesartan was associated with cost
savings of E15 397 and E9 526 per patient in Belgium,
and E20 550 and E13 617 in France, vs amlodipine and
control, respectively. These results were consistent
with published results for Germany, Hungary, Italy,
Spain, the UK and the US. Eighty percent of overall
savings were achieved within 9–11 years of treatment in
Belgium, France and Spain.
Irbesartan, in fact, resulted in cost savings very early,
usually within 2–3 years of treatment. This was the case
in the Belgian, French, Italian, Spanish, UK and US
settings. In the Belgian setting, after only 5 years, costs
savings were E5335 and E3163 vs amlodipine and the
control, respectively. In the French setting these savings
were E7715 and E5164 vs amlodipine and the control,
respectively. Cost savings in the UK setting due to
avoided or delayed ESRD were evident after 3 years
compared to the amlodipine group, and after 4 years
compared to the control group. In the US setting, the
model predicted that irbesartan would save E3462
and E2280 compared with amlodipine and the control,
respectively, after 3 years.
Table 3. Summary of total mean lifetime cost per patient (25 years)
Country/discount rate Mean total lifetime cost per patient (E) Mean cost of ESRD per patient (E)
(percentage of mean total lifetime cost)
Irbesartan Amlodipine Control Irbesartan Amlodipine Control
Belgium/3% [13] 79 080 100 878 91 321 74 722 (94%) 97 708 (97%) 90 067 (99%)
France/3% [13] 95 198 122 809 111 886 92 081 (97%) 120 113 (98%) 110 782 (99%)
Germany/5%a [14] 45 430 60 356 54 454 – – –
Hungary/5% [15] 41 488 51 646 46 824 36 950 (89%) 48 878 (95%) 45 025 (96%)
Italy/5%a [16] 41 692 55 222 49 825 37 257 (89%) 51 531 (93%) 47 514 (95%)
Spain/6% [17] 51 969 66 052 59 830 47 512 (91%) 62 768 (95%) 57 841 (97%)
UK/6%a [18] 30 627 40 208 36 138 26 094 (85%) 36 633 (91%) 33 969 (94%)
US/3% [12] 91 672 113 257 104 482 – – –
a10 year data available only.
Table 2. Summary of life expectancy projections (25-year timeframe)
Country/discount rate Mean undiscounted life expectancy (years) Mean discounted life expectancy (years)
Irbesartan Amlodipine Control Irbesartan Amlodipine Control
Belgium/3% [13] 10.59 9.88 9.68 8.57 8.11 7.95
France/3% [13] 10.61 9.92 9.71 8.58 8.13 7.97
Germany/NR [14] – – – – – –
Hungary/5% [15] 11.60 11.32 10.98 8.03 7.87 7.67
Italy/5% [16] 10.79 10.20 9.95 7.63 7.63 7.17
Spain/6% [17] 11.08 10.62 10.33 7.32 7.11 6.95
UK/1.5% [18] – – – – – –
US/3% [12] – – – 7.99 7.34 7.23
NR, not reported.
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Sensitivity analyses
The sensitivity analyses in all countries determined that
the parameter with the greatest single impact on life
expectancy was the annual probability of death in
patients with overt nephropathy but no progression
to DSC and ESRD (taken from the IDNT), closely
followed by the annual probability of death in patients
with ESRD receiving dialysis (taken from country-
speciﬁc published sources). Any treatment which
reduces the incidence of ESRD would be expected,
therefore, to prolong life signiﬁcantly. In the Spanish
study, it was determined that irbesartan would remain
life saving compared to amlodipine with up to a 10%
increase in the probability of dying in patients with
overt nephropathy but no progression to DSC and
ESRD in the irbesartan treatment arm. This prob-
ability could be increased by as much as 18% with
irbesartan remaining life saving compared to the
control treatment.
Since the parameter with the greatest single impact
on total lifetime costs was the annual cost of dialysis,
one would expect that treatments which lowered
the likelihood of dialysis being required would be
expected to lower costs. By signiﬁcantly reducing the
incidence of ESRD, irbesartan treatment both extended
life and reduced total costs in all of the countries
reviewed.
Discussion and conclusions
Type 2 diabetes patients with overt nephropathy and
hypertension are at a very high risk of developing
ESRD. It was hypothesized that, based on the results
of the IDNT where irbesartan signiﬁcantly reduced
the progression from overt nephropathy to DSC and
ESRD, treatment with irbesartan may have a sub-
stantial impact on the clinical outcomes and costs in
this patient group. This review identiﬁed a number of
studies where various country-speciﬁc clinical and costs
data were processed through one published and peer-
reviewed pharmacoeconomic Markov model. Where
life expectancy was analysed, improvements in life
expectancy were forecast with irbesartan treatment vs
amlodipine and vs the control after 10 years. The
anticipated gains in life expectancy, due to delay in
the onset of ESRD, compare very well with other
established interventions in healthcare [22,23]. A
reduction in overall costs per patient was observed
with irbesartan treatment compared to amlodipine or
control in all eight countries reviewed. In Belgium,
France, Italy, Spain, the UK and the US cost savings
were evident after 3 years.
The sensitivity analyses performed in the modelling
studies demonstrated that these ﬁndings were robust
under variation in a range of assumptions. Key factors
were the probabilities of mortality in patients with
either overt nephropathy before progression to more
serious disease (derived from IDNT data), and in those
with ESRD (derived from country-speciﬁc data).
The key costs driver was the costs associated with
dialysis.
Pharmacoeconomic modelling is commonly used in
health economics, but it has some limitations that
should be considered to place these ﬁndings properly
into context. In order to translate changes in inter-
mediate clinical outcomes to long-term costs, projec-
tions are made beyond known clinical trial periods,
which requires assumptions to be made on the long-
term effects of treatment in a given patient population.
For example, patients in the IDNT were followed for
a mean duration of 2.6 years. A longer-term study may
have produced results that were more meaningful
for cost-effectiveness projections with long timeframes.
It could also be argued that modelling studies based
on clinical trials do not accurately reﬂect the real-life
situation, as they fail to take into account issues such
as compliance, patient and physician preference, etc.
Moreover, since costs are based on current ﬁgures,
they may not truly reﬂect future costs despite the
application of discounting. However, in the absence
of large-scale, long-term epidemiological study data,
modelling is a valuable technique by which long-term
predictions can be made to assist healthcare decision-
makers determine how best to allocate scarce health
resources.
Table 4. Summary of projected cost savings (E)
Country Lifetime
25-year timeframe 10-year timeframe
Irbesartan vs amlodipine Irbesartan vs control Irbesartan vs amlodipine Irbesartan vs control
Belgium [13] 21 798 12 241 15 397 9526
France [13] 27 611 16 688 20 550 13 617
Germany [14] – – 15 445 9338
Hungary [15] 10 158 5336 5675 3046
Italy [16] 17 003 9418 13 530 8133
Spain [17] 14 083 7861 10 261 6175
UK [18] 13 457 7300 7515 4280
US [12] 21 585 12 810 19 555 13 158
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Another potential limitation of this study is that our
literature search identiﬁed seven publications based
on the same Markov model, adapted using country-
speciﬁc data to project and evaluate the clinical beneﬁts
and costs of irbesartan vs amlodipine and a control.
It would have been interesting to have included data
on the same interventions from a different model
perspective of nephropathy to extend the comparison
of ﬁndings further.
A number of key assumptions were made in the
published modelling analyses that may have had an
impact on their ﬁndings. For example, in all three
treatment arms in the model, it was assumed that the
transition probabilities returned to those of the control
group after the 3-year trial period. In other words, only
the trial effects of irbesartan and amlodipine were
considered. This may have biased the analyses against
irbesartan, as its renoprotective effects could well have
been sustained beyond the trial period. However, this
conservative assumption was made as it remains
uncertain whether the observed effect of irbesartan
would be sustained over a 10-year or 25-year period. It
was also assumed that the mortality rates from the
IDNT would remain constant for the ﬁrst 10 years of
the simulation [11]. This could also be biased against
irbesartan, but the long-term inﬂuence which treat-
ment with irbesartan has on delaying the onset of
ESRD is not known. Another signiﬁcant assumption
made was that the acquisition costs of medications
would remain constant over the 10-year simulation
period. The possibility, therefore, of medications
becoming cheaper in the future due to loss of patent
protection was not taken into account. This may have
overestimated the costs of irbesartan in the future, and
may have therefore underestimated any cost savings
that could be expected. It was assumed, conservatively,
that in the absence of published comparisons of the
effects of irbesartan, amlodipine and a standard control
of hypertension in patients with ESRD, the probabil-
ities of death or changing between dialysis and renal
transplant states were not dependent on treatment arm
if ESRD developed in a patient during the simulation.
Therefore, it was not possible to analyse the inﬂuence
that the various treatment arms may have had on the
course of ESRD.
One of the shortcomings of the IDNT, and therefore
in the modelling analyses based upon it, is that it did
not include angiotensin-converting enzyme inhibitors,
beta-blockers or other angiotensin 2 receptor blockers
as treatments for type 2 diabetes patients with
nephropathy and hypertension. Where type 1 diabetes
and non-diabetic renal impairment have been modeled,
it has been suggested that angiotensin-converting
enzyme inhibitors may produce long-term cost savings
[24–28]. A recent head-to-head trial compared the
renoprotective effects of the ACE-inhibitor enalapril
20mg daily vs the angiotensin II-receptor blocker
telmisartan 80mg daily in patients with type 2 diabetes
and nephropathy [29]. Study endpoints included the
change in glomerular ﬁltration rate over 5 years, rates
of ESRD and cardiovascular events; and rate of death
from all causes. Telmisartan was found to be non-
inferior to enalapril as a renoprotective agent in this
patient group, but no conclusions could be drawn as
to whether or not this applied to patients with more
advanced nephropathy. Further trials comparing irbe-
sartan with ACE-inhibitors are required in patients
with type 2 diabetes and patients with nephropathy
and hypertension before modelling studies can be
performed to project the long-term effects in this
population.
With the exception of the German study, where
life expectancy data were not published, the model-
ling studies reviewed conﬁrmed that a reduction in
progression to DSC and ESRD associated with
irbesartan treatment led to an important improve-
ment in life expectancy. A reduction in total lifetime
costs of medications and ESRD per patient com-
pared to treatment with amlodipine or the control
was reported in all eight settings. Based on the
published modelling studies, it appears that irbesar-
tan has a valuable role to play in reducing the huge
clinical and economic burden associated with ESRD
in patients with type 2 diabetes, advanced overt
nephropathy and hypertension.
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